Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nbt0119-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperthyroidism crisis and complex pancytopenia: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Endocrinology, First Affiliated Hospital of Army Medical University, Chongqing 400038.
Antithyroid drugs can cause neutropenia or agranulocytosis, rarely pancytopenia in hyperthyroidism therapy. The treatment is difficult and lethality is high when granulocytopenia or pancytopenia combined with hyperthyroidism crisis. First Affiliated Hospital of Army Medical University treated a patient who had pancytopenia caused by methimazole with systemic lupus erythematosus, secondary hyperthyroidism crisis and agranulocytosis.
View Article and Find Full Text PDFFatal and sp. co-infestation in wolves () at the Białowieża National Park, Poland - is it a consequence of climate change?
J Vet Res
December 2024
Department of Virology, National Veterinary Research Institute, 24-100 Puławy, Poland.
Introduction: In winter 2021/2022, a wolf population in the primeval Białowieża Forest in Poland was struck by an outbreak of severe mange caused by mixed infestations of and mites. We present an epidemiological analysis of this mange which caused significant morbidity and mortality.
Material And Methods: Ten sites known for wolf activity were monitored by camera trapping.
Oral Pathogens' Substantial Burden on Cancer, Cardiovascular Diseases, Alzheimer's, Diabetes, and Other Systemic Diseases: A Public Health Crisis-A Comprehensive Review.
Pathogens
December 2024
College of Dentistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
This review synthesizes the findings from 252 studies to explore the relationship between the oral pathogens associated with periodontitis, dental caries, and systemic diseases. Individuals with oral diseases, such as periodontitis, are between 1.7 and 7.
View Article and Find Full Text PDFEfficacy and safety of guselkumab in patients with active lupus nephritis: results from a Phase 2, randomized, placebo-controlled study.
Rheumatology (Oxford)
December 2024
The Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Objective: Evaluate the efficacy and safety of guselkumab, an interleukin (IL)-23 inhibitor, in a Phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active lupus nephritis (LN).
Methods: Adults (18-75 years) with active LN (Class III-IV proliferative nephritis [kidney biopsy] and urine protein-to-creatinine ratio [UPCR)] of ≥ 1 mg/mg despite standard-of-care therapy) were randomized (1:1; planned sample = 60) to receive intravenous infusions of guselkumab 400 mg or placebo at Weeks 0, 4, and 8, then subcutaneous injections (guselkumab 200 mg or placebo) at Week12 and every 4 weeks through Week48 in addition to their background therapy. The primary end point was achievement of ≥ 50% decrease in proteinuria from baseline at Week24.
Autoimmune Health Crisis: An Inclusive Approach to Addressing Disparities in Women in the United States.
Int J Environ Res Public Health
October 2024
Society for Women's Health Research, Washington, DC 20036, USA.
Autoimmune diseases are identified by the chronic inflammation and tissue damage resulting from unregulated immune responses throughout the body. Systemic lupus erythematosus, type 1 diabetes mellitus, and Hashimoto's thyroiditis are among the 80+ characterized conditions, 80% of which are diagnosed in women. The compounded effects of biological sex and hormones; social identities, such as age, race, and gender; and other determinants on health highlight a pressing need for an inclusive approach to address disparities for women living with autoimmune diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!